Table 1

Parameters	TREATEMENT GROUP(N=26)	CONTROL GROUP(N=23)	p-value
Age (years)	54.18 ± 16.18	51.67 ± 12.27	NS
Female n (%)	7 (26.9%)	3 (13.05%)
Male n (%)	19 (73.1%)	20 (86.95%)
Weight (Kg)	85.43 ± 11.73	85.96 ± 16.85	NS
BMI (Kg/m^²)	30.73 ± 3.76	28.67 ± 4.40	NS
ALT (U/L)	68.54 ± 13.58	64.95 ± 14.14	NS
AST (U/L)	48.38 ± 12.71	46.00 ± 12.09	NS
GGT (U/L)	108.19 ± 74.98	65.91 ± 32.23	= 0.01
CAP (dB/m)	278.96 ± 24.11	262.96 ± 33.85	NS
Liver stiffness (kPa)	5.85 ± 0.85	5.69 ± 2.26	NS
FIB4	1.51 ± 0.64	1.31 ± 0.60	NS
FBG (mg/dL)	97.58 ± 11.87	99.78 ± 10.01	NS
HOMA-IR	2.90 ± 0.97	2.83 ± 1.02	NS
Insulinemia (µU/mL)	12.07 ± 4.10	11.34 ± 3.40	NS
Ferritin (ng/mL)	208.46 ± 116.05	285.48 ± 128.12	NS
SBP (mmHg)	131.54 ± 10.75	119.13 ± 15.05	NS
DBP (mmHg)	85.00 ± 12.00	89.13 ± 20.09	NS

Table 1: Baseline demographics and patient characteristics

All data are presented as mean ± SD. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; DBP, diastolic blood pressure; FBG, fasting blood glucose, FIB-4, Fibrosis-4 Index; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; LDL, low-density lipoprotein; NS, Non-significant; SBP, systolic blood pressure.

Table 2

Parameters	TREATEMENT GROUP			CONTROL GROUP
	T0	T1	p-value	T0	T1	p-value
Weight (Kg)	85.43 ± 11.73	82.27 ± 10.61	<0.001	86.96 ± 16.85	83.92 ± 16.49	<0.05
BMI (Kg/m^²)	30.73 ± 3.76	29.61 ± 3.61	<0.001	28.67 ± 4.40	28.07 ± 4.38	<0.05
FBG (mg/dL)	97.58 ± 11.87	94.35 ± 8.09	<0.05	99.78 ± 10.01	97.57 ± 10.90	NS
Insulinemia (µU/mL)	12.07 ± 4.10	10.75 ± 2.86	<0.05	11.34 ± 3.40	11.76 ± 3.08	NS
HOMA-IR	2.90 ± 0.97	2.50 ± 0.67	NS	2.83 ± 1.01	2.87 ± 0.95	NS
Cholesterol (mg/dL)	208.96 ± 29.57	204.73 ± 23.97	NS	204.26 ± 21.53	208.87 ± 27.56	NS
LDL (mg/dL)	134.8 ± 25.8	125.7 ± 24.0	<0.05	126.20 ± 32.97	126.89 ± 28.17	NS
HDL (mg/dL)	51.54 ± 8.79	56.27 ± 8.48	<0.0001	54.43 ± 10.24	54.65 ± 7.85	NS
Triglycerides (mg/dL)	131.50 ± 33.05	134.19 ± 26.32	NS	136.83 ± 48.31	136.61 ± 46.35	NS
FIB4	1.51 ± 0.63	1.36 ± 0.56	<0.05	1.31 ± 0.60	1.35 ± 0.68	NS
Liver stiffness (kPa)	5.85 ± 0.85	5.39 ± 0.87	<0.001	5.69 ± 2.26	5.76 ± 2.26	NS

Table 2: Descriptive statistics (mean ± standard deviation), within-groups, for outcome measures in the two study groups

All data are presented as mean ± SD. Within-group changes from baseline to post-intervention. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FBG, fasting blood glucose; FIB-4, Fibrosis-4 Index; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment-insulin resistance; LDL, low-density lipoprotein. NS, Non-significant.

Tables at a glance

Table 1

Table 2

Figures at a glance

Figure 1

FIGURE 1

Figure 1: Liver enzymes levels change from baseline to post-intervention in treatment and control groups

Reduction of liver enzymes levels from baseline to post-intervention in treatment and control groups. Dark column represents the enzymes levels at the baseline and light column the enzymes levels after 4-months of the food supplements plus diet or only diet, respectively. All data are presented as mean ± SD. a) shows alanine aminotransferase (ALT) levels, b) aspartate aminotransferase (AST) levels and c) gamma-glutamyl transferase (GGT) levels within-group changes from baseline to post-intervention. * p-value T0 vs T1; # p-value T1 vs T1.